Page 2 - Biocon

India Inc's earnings pulse weakens after Q1: Top 5 EPS upgrades, downgrades

Brokerages trim FY26 estimates for 130 of 192 BSE 200 companies, with a median EPS downgrade of 3.5%

India Inc bonds resilient amid record trade costs from US tariffs: Barclays

Barclays says Indian corporates will face margin compression but remain supported by strong leverage, liquidity and domestic demand as US tariffs hit $55 bn exports

Biocon shares slip 3% as Q1 results miss estimates; should you sell?

Biocon shares fell 3 per cent after it reported a 95.2 per cent decline in net profit in Q1FY26

Confident about Biocon's response to US tariffs: Kiran Mazumdar-Shaw

We remain confident in our global footprint and are well positioned to respond once more details are available. , said Biocon Chairperson

Stocks to Watch today, Aug 8: Titan, BSE, Biocon, LIC, Godrej Consumer

Stocks to Watch today, August 8, 2025: Titan, BSE, LIC, Godrej Consumer Products, and Biocon are some of the key stocks to watch today

Biocon Q1 results: Net profit down 95%, revenue rises 15% to ₹4,022 cr

Biocon's Q1 net profit declines sharply due to high base from one-time gain last year; biosimilars, CRDMO and generics drive revenue and operational growth

Biocon Biologics appoints Deepali Naair Global Head, Brand & Corp Comm

Biocon Biologics on Wednesday announced the appointment of Deepali Naair as Global Head Brand & Corporate Communications, effective immediately. Deepali will lead the global brand and corporate communications function, responsible for defining and executing an integrated strategy that spans brand positioning, digital presence, regulatory and statutory communications, financial and corporate reporting, media relations, and employer branding, Biocon Biologics, a subsidiary of Biocon Ltd, said in a statement. With over three decades of experience across India, ASEAN, and Australia, Naair brings deep expertise in brand building, marketing, and corporate reputation. In her most recent role as Group Chief Marketing Officer at CKA Birla Group, she was instrumental in shaping the Group's corporate identity, launching new brands, and driving strategic transformations, Biocon Biologics stated. Naair will join the company's Executive Leadership Team (ELT) and report directly to Shreehas ...

Deepali Naair to lead Brand & Corporate Communications at Biocon Biologics

Naair will lead Biocon Biologics' global brand and corporate communications strategy as part of its executive team, reporting directly to CEO and MD Shreehas Tambe

Biocon Biologics expands diabetes portfolio with FDA approval for Kirsty

Interchangeable biosimilar to NovoLog in the US and will be available in prefilled pens and vials

Biocon Biologics gets UK MHRA nod for biosimilars Vevzuo, Evfraxy

Biocon Ltd on Monday said its arm Biocon Biologics Ltd has received marketing authorisations from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for Vevzuo and Evfraxy, biosimilars of Denosumab used in the treatment of bone-related diseases. Vevzuo is authorised for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone, Biocon said in a regulatory filing. It is also authorised for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. On the other hand, Evfraxy is authorised for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, the company said. In postmenopausal women, this significantly reduces the risk of vertebral, non-vertebral, and hip fractures, it ...

Biocon Biologics gets EU nod for two drugs to treat bone diseases

Biocon Biologics receives marketing authorisation from the European Commission for two Denosumab biosimilars, Vevzuo and Evfraxy, expanding its portfolio in bone disease treatment

Karnataka CM's remark on Covid vaccines 'factually incorrect': Biocon chief

Biocon founder Kiran Mazumdar-Shaw on Thursday opposed Karnataka Chief Minister Siddaramaiah's remarks linking covid-19 vaccines with a spate of heart attack deaths in the state's Hassan district, saying such claims are "'factually incorrect" and "misleading". Siddaramaiah has suggested that the recent heart attack deaths in Hassan district may be linked to the vaccination drive. He had also claimed the vaccines were 'hastily' approved. In a social media post, Shaw said "covid-19 vaccines developed in India were approved under the Emergency Use Authorisation framework, following rigorous protocols aligned with global standards for safety and efficacy. To suggest that these vaccines were 'hastily' approved is factually incorrect and contributes to public misinformation." "These vaccines have saved millions of lives and, like all vaccines, may cause side effects in a very small number of individuals. It is important to acknowledge the science and data-driven processes behind their ...

Biocon climbs 3% on plans to file approvals for generic weight-loss drug

Biocon share price gained 2.5 per cent after reports suggested that the company is planning to file for generic versions of Novo Nordisk A/S's Ozempic and Wegovy

Biocon eyes early lead in generic Wegovy, Ozempic sales in Canada from 2026

The Bengaluru-based company is seeking approval of generic Ozempic by September from Canadian authorities, and also in some emerging markets, its managing director, Siddharth Mittal said

Biocon Biologics to launch Eylea biosimilar Yesafili in Canada next month

Yesafili is the first Eylea biosimilar approved in Canada and Biocon Biologics' 10th commercialised biosimilar, with launch scheduled for July 4 across the country

Dividend stocks! M&M, 34 others to go ex-date next week; do you own any?

Container Corporation, and Paras Defence will also remain in focus, as the former has announced bonus issue of equity shares for its shareholders, while the latter has announced stock-split

Biocon's ₹4,500 crore equity raise to reduce debt by FY26, says S&P

S&P says Biocon will bring down adjusted debt to Rs 20,000 crore by FY26 through equity issuance, with strong cash flows aiding deleveraging and future capex needs

Decision on merger with Biocon Biologics soon, says Siddharth Mittal

We are talking about the GLP-1 opportunity and our strong franchise in insulins. There is a huge demand in the global diabetes-obesity segment, said Siddharth Mittal

Biocon closes ₹4,500 crore QIP to boost innovation, expand global access

Biocon raises ₹4,500 crore through QIP, its first equity issue since IPO, to fund innovation, repay debt, and expand global access to affordable biopharmaceuticals

Stocks to Watch today, June 17: NTPC, Vishal Mega Mart, Sona BLW, Zee Ent

Stocks to Watch today, June 17, 2025: Asian Paints, Sona BLW, Tanla Platforms, Mphasis are among shares to remain focus